Physician profile
Tiffany A Dotson
NPI 1033459672
$1,582.66
in general payments reported to CMS, 2019-2025
10 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $24.42 · 2024: $385 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,014 · Food and Beverage: $468 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,014.25 |
| Food and Beverage | $468.41 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,114.25 | 2025 | |
| Janssen Biotech, INC. | $119.61 | 2024 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $116.33 | 2024 | |
| Boston Scientific Corporation | $58.75 | 2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $56.61 | 2024 | Omvoh |
| Evoke Pharma, INC. | $38.66 | 2024 | |
| Smith+Nephew, INC. | $26.24 | 2024 | Stravix |
| Supernus Pharmaceuticals, INC. | $24.42 | 2023 | Qelbree |
| Lundbeck LLC | $14.20 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $13.59 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Dotson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.